Bezlotoxumab Disease Interactions

Heart failure was reported more frequently with bezlotoxumab than with placebo in two Phase 3 clinical trials, and occurred primarily in patients with underlying congestive heart failure (CHF). In patients with a history of CHF, 12.7% (15/118) of bezlotoxumab-treated patients and 4.8% (5/104) of placebo-treated patients had heart failure as an adverse reaction during the 12-week study period, and 19.5% (23/118) versus 12.5% (13/104) died, respectively. The causes of death varied and included cardiac failure, infections, and respiratory failure. Therapy with bezlotoxumab should be reserved for use only when the benefit outweighs the risk in patients with a history of CHF.

Bezlotoxumab should be used with caution in patients with a history of congestive heart failure, and it should be reserved for use when the benefits outweigh the risk.